Lower riskDrug recall · FDA · Published May 9, 2023
B. Braun Medical Heparin Injection Recall: Subpotent Risk
B. Braun Medical recalls heparin sodium injections with low anti-factor IIa potency. This may cause ineffective blood clotting. Affected products have specific lot numbers and expiration dates.
“B. Braun Medical Heparin Injection Recall: Subpotent Risk.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/33493-b-braun-medical-heparin-injection-recall-subpotent-risk. Based on FDA recall #D-0579-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0579-2023%22&limit=1).
B. Braun Medical Inc. recalled Heparin Sodium injection nationwide on May 9, 2023, due to subpotent low anti-factor IIa potency, the FDA said. The voluntary Class II recall affects 1,380 units distributed across the United States.
How to tell if you have it
Brand: B. Braun Medical
Product: Heparin Sodium, 25,000 USP units per 250mL, (100 USP units per mL) in 5% Dextrose injection, 250 ml Excel Container
NDC: 0264-9587-20
Lot Number: J1P154N
Expiration Date: 31 May, 2023
The hazard
The recalled Heparin Sodium injection presents a subpotent hazard characterized by low anti-factor IIa potency. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show B Braun Medical Inc has issued 66 other recalls since October 15, 2013. Recent similar product recalls include Somerset Therapeutics Cisatracurium Besylate Injection (November 26, 2025), Lupin Ganirelix Acetate Injection (November 13, 2025), and Par Health Buprenorphine Injection (June 12, 2026).
How to tell if you have this one
Check for the product name: Heparin Sodium, 25,000 USP units per 250mL in 5% Dextrose injection. Look for the lot number J1P154N and expiration date of May 31, 2023.
Brand
B. Braun Medical
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Details
Verify the lot number and expiration date on the product label.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 10 months after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0579-2023 (May 9, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0579-2023 to see it in context.
Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.